KRAS and neoplasm: The KRAS-variant has not been found to be associated with tumor acquired KRAS mutations, and while not mutually exclusive, is found less frequently in patients with NSCLC who have tumor acquired EGFR or KRAS mutations (4% and 11%, respectively, vs. ∼17%–20%, (10, 11)].